

Rec'd PATENT

541 604
07 JUL 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



10/541604



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065390 A1

(51) International Patent Classification⁷: C07D 495/04,
295/04

(21) International Application Number:
PCT/EP2004/000299

(22) International Filing Date: 16 January 2004 (16.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
103 01 923.5 17 January 2003 (17.01.2003) DE

(71) Applicant (for all designated States except US): KRKA,
TOVARNA ZDRAVIL, D.D., NOVO MESTO [SI/SI];
Smarjeska cesta 6, 8501 Novo mesto (SI).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LENARSIC, Roman
[SI/SI]; Trzaska cesta 266/B, 1000 Ljubljana (SI).

(74) Agents: GROSS, Ulrich-Maria et al.; Uexküll & Stol-
berg, Beselerstrasse 4, 22607 Hamburg (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE



(I)




(II)

(57) Abstract: The invention provides an improved process for preparing Olanzapine as well as intermediates therefor.

WO 2004/065390 A1

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE

The invention belongs to the field of organic chemistry and relates to a new process and intermediates for the manufacture of a compound having the following formula I:




i.e. 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b]-[1,5]benzodiazepine (hereinafter referred to by its generic name "Olanzapine").

Olanzapine is a serotonin (5-HT₂) and dopamine (D₁/D₂) receptor antagonist with anticholinergic activity. It is useful in treating psychotic conditions such as schizophrenia, schizophreniform disorders, acute mania, states of mild anxiety and psychosis.

Heretofore, only a few processes for the manufacture of Olanzapine have become known.

British patent GB 1,533,235 discloses a series of thieno[1,5]-benzodiazepine derivatives which are represented by the following generic formula:



CONFIRMATION COPY


wherein R^A and R^B represent various substituents, e.g. hydrogen, R^C represents amine substituents, e.g. 4-methylpiperazinyl, and T represents thiophene rings fused to the [1,5]-benzodiazepine ring. An example of these derivatives is 2-methyl-10H-thieno-
5 [2,3-b][1,5]benzodiazepine. These benzodiazepine derivatives are prepared by reacting a suitable precursor with an amine HR^C, so as to introduce the amine substituent R^C in the molecule.

Olanzapine and its synthesis were specifically disclosed in EP 0
10 454 436 A1. This application discloses two synthetic paths, which are depicted in scheme 1 below.

Both paths start with a Gewald reaction to form appropriately substituted 2-amino-thiophenes (a). This type of reaction is
15 described in *Chem. Ber.* 1965, 98, 3571-3577; *Chem. Ber.* 1966, 99, 94-100. The second step involves the reaction of 2-amino-thiophene with 2-nitro-1-fluorobenzene (b), to give a 2-(2-nitro-anilino)thiophene.

20 According to the first reaction path, this thiophene is then (c) reduced and cyclised to a benzodiazepine-4-amine hydrochloride. Replacement of the amine group by 1-methylpiperazine (d) leads to the desired Olanzapine.

25 In the second reaction path, the thiophene is catalytically hydrogenated to an amino-ester (e), which is then transformed into an amino-amide (f), and this amino-amide is subsequently cyclised (g) to give Olanzapine. This second approach requires chromatographic purification in each step, because the reactions
30 lack selectivity and because the products could not be obtained by precipitation.

Scheme 1:

In path 1, X is CN and in path 2, X is COOR, e.g. COOC₂H₅.

The reagents used in the respective steps of the reactions were as follows: (a) Et₃N, DMF; (b) NaH, THF; (c) SnCl₂, HCl; (d) DMSO, toluene; (e) H₂, Pd/C, EtOH-EtOAc; (f) TiCl₄, anisole; (g) TiCl₄, anisole.

Besides the already mentioned requirement for chromatographic purification in early steps, causing high costs, low yields and substantial amounts of waste products, both paths have some further drawbacks. They provide only low yields, e.g. in the case of path 2 with X being COOC₂H₅, the yield of the first step


is only 42.5 % as is reported in *J. Heterocyclic Chem.* 36, 1999, 333-345. Other drawbacks are that expensive compounds such as Pd have to be used as well as compounds that are toxic and not acceptable from an environmental point of view, like DMF, TiCl_4 or SnCl_2 .

Thus, there exists a need for an improved process which overcomes these drawbacks.

10 This object is surprisingly solved by the process for the manufacture of Olanzapine according to claims 1 to 5. The invention is also directed to the compounds according to claims 6 to 9 as well as to their use according to claim 10.

15 The process according to the invention for the manufacture of Olanzapine is characterized by converting a compound of the following formula II or a salt thereof

20



25 in which

(i) R1 and R2 together form $=\text{CH}-\text{CH}_2-\text{CH}_3$, or

(ii) R1 and R2 are both H, or

30

(iii) R1 is H and R2 is $-\text{CH}(\text{R}_3)-\text{CH}_2-\text{CH}_3$, wherein R3 is a leaving group, that can be eliminated together with R1 to result in R1 and R2 together forming $=\text{CH}-\text{CH}_2-\text{CH}_3$,


35

to give Olanzapine or a salt thereof.

In the case of (i) the compound to be converted is the

propylidene-diazepine of the following formula III:

5




III.

10 or a salt thereof.

In the case of (ii) the compound to be converted is the diazepine of the following formula IV:

15




IV

20

or a salt thereof.

In the case of (iii) the compound to be converted is the diazepine-derivative bearing a leaving group R₃, as is shown in the following formula V:

30




V

35 or a salt thereof.


A preferred leaving group R₃ is -OR₄.

R4 can preferably be H, so that the leaving group R3 is preferably an alcohol group. In such a case the compound to be converted is the diazepine-alcohol of the following formula VI:



or a salt thereof.

R4 can also be selected from the group of acyl, sulfonyl, preferably trifluoroacetyl and methane sulfonyl, so that the leaving group R3 is an ester group, and the compound to be converted is the benzodiazepine-ester of the following formula VII:




or a salt thereof with R4 being preferably selected from the group of acyl, sulfonyl, and with R4 most preferably being trifluoroacetyl or methane sulfonyl.

In a particularly preferred embodiment of the process according to the invention, R1 and R2 together form $=CH-CH_2-CH_3$, and the conversion is performed by reacting the compound of formula II with a source of sulfur.

Particularly preferred embodiments of the process according to this invention are depicted in scheme 2, using the preferred precursors of the invention.

Scheme 2:



The reagents used in the respective steps are preferably as follows:

(a) Toluene, DMSO; (b) 1. LDA, THF, 2. (CF₃CO)₂O, NaOH; (c) LDA, THF; (d) (CF₃CO)₂O, NaOH, THF; (e) [S], R¹NR²R² or AHB or AH.

Besides the advantage of the high yields in the synthesis, the use of symmetrical intermediates according to the present invention is particularly advantageous because the possibility of obtaining undesired regioisomers is excluded.

Thus, in a first preferred aspect of the invention Olanzapine can be produced in a reaction (e) of the propylidene-benzodiazepine of formula III with a source of sulphur [S], preferably elementary sulphur or sodium polysulphide, which is usually base mediated. An appropriate base can be chosen among secondary or tertiary alkylamines of formula R¹NR²R², in which R¹ is H or R², and R² is a C₁- to C₅-alkyl or cyclic amine such as

morpholine, piperidine, piperazine or 1-methyl-piperazine. Preferably the base is chosen from tertiary alkyl-amines and the most preferable base is triethylamine. Acceptable solvents for the reaction are *N*-methyl-imidazole, dimethyl sulfoxide (DMSO),
5 C₁- to C₅-aliphatic alcohols, alcoholamines, diols, polyols or mixtures thereof, preferably mixtures of dimethyl sulfoxide and alcohols. An appropriate reaction temperature range is from room temperature to the boiling point of the reaction mixture, preferably from 50°C to 150°C and most preferably is a reaction
10 temperature of about 100°C.

The reaction can also be mediated with a salt AHB. This salt is composed of an acid AH and an amine B. The acid AH can be chosen among organic or anorganic acids. Preferred are organic car-
15 boxylic or sulfonic acids, such as acetic acid, trifluoroacetic acid, benzoic acid, 4-nitrobenzoic acid, 4-chlorobenzoic acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid or *p*-toluenesulfonic acid and most preferred are
20 *p*-toluenesulfonic acid or methanesulfonic acid. The amine B can be chosen among secondary or tertiary aliphatic or aromatic amines. Preferred aromatic amines are pyridine picoline, lutidine, quinoline, 2-methylquinoline or 1-methylimidazole and most preferred are pyridine or quinoline. Either part of the salt AHB can be polymer bound. Acceptable solvents for the reaction are
25 high boiling point solvents. They can be hydrocarbons, ethers, esters, nitriles or alcohols or mixtures thereof. Preferred are aromatic ethers, esters, or nitriles, such as anisole, dimethoxybenzene, diphenyl ether, methyl benzoate, ethyl benzoate and benzonitrile and most preferred is benzonitrile. An appro-
30 priate reaction temperature range is from 80°C to 220°C, preferably from 100°C to 180°C and most preferred is a reaction temperature of about 140°C.

The propylidene-benzodiazepine of formula III can preferably be
35 synthesised via step (b) from the benzodiazepine of formula IV. In a preferred embodiment the benzodiazepine IV is firstly transformed to an alkali salt using strong bases such as alkali amides, alkali alkyls or alkali silazanes. Preferably lithium

diisopropylamide (LDA) or butyl-lithium is used and most preferably lithium diisopropylamide is used. In an addition reaction of the alkali salt of the benzodiazepine IV to propionaldehyde the benzodiazepine-alcoholate of the alcohol of formula VI is
5 formed. The solvent for this reaction should be inert to strong bases and it is in particular chosen from ethers or aromatic hydrocarbons. Water miscible ethers are preferred, with the most preferable solvent being THF. Usual reaction temperatures range from -50 °C to room temperature, preferably from -30 °C to 0 °C.
10 The benzodiazepine-alcoholate is then transformed to a benzodiazepine-ester of formula VII, in which R₄ is in particular selected from the group of acyl or sulfonyl, preferably acetyl trifluoroacetyl or methane sulfonyl, with trifluoroacetyl being most preferred. The elimination of said ester group to
15 produce the propylidene-benzodiazepine of formula III is accomplished by adding of an aqueous solution of alkali hydroxide salts such as lithium hydroxide, sodium hydroxide or potassium hydroxide and preferably is an aqueous solution of sodium hydroxide. When the organic solvent is immiscible with water,
20 the reaction can be catalysed with quarternary ammonium salts, such as tetraalkylammonium chlorides, bromides, fluorides, hydroxides or cyanides, wherein "alkyl" represents groups having 1 to 8 carbon atoms. Preferably the reaction is catalysed with tetrabutylammonium bromide or hydroxide and most preferably with
25 tetrabutylammonium bromide. It is most preferable that the sequence of these reactions is conducted as a one pot reaction.

Alternatively, the propylidene-diazepine of formula III can be prepared via step (d) starting from the benzodiazepine-alcohol
30 of formula VI. The procedure is similar to the second part of step (b). The benzodiazepine-alcohol is first transformed to a diazepine-ester of formula VII, in which R₄ is in particular selected from the group of acyl or sulfonyl, preferably acetyl, trifluoroacetyl or methane sulfonyl, with trifluoroacetyl being
35 most preferred. The elimination of the ester group to produce the propylidene-benzodiazepine of formula III is preferably carried out in a one or two phase solvent system. The organic solvent can be chosen from ethers, halogenated hydrocarbons or

aromatic or aliphatic hydrocarbons and is preferably chosen from tetrahydrofuran, dichloromethane or toluene, with the most preferable solvent being tetrahydrofuran. The second solvent can be an aqueous solution of alkali hydroxide salts such as lithium hydroxide, sodium hydroxide, or potassium hydroxide and preferably is an aqueous solution of sodium hydroxide. In case of a two phase solvent system, the reaction can be catalysed with quarternary ammonium salts such as tetraalkylammonium chlorides, bromides, fluorides, hydroxides or cyanides, wherein "alkyl" represents groups having 1 to 8 carbon atoms. Preferably the reaction is catalysed with tetrabutylammonium bromide or hydroxide and most preferably with tetrabutylammonium bromide. It is most preferable that esterification and subsequent elimination of the resulting ester group are conducted as a one pot reaction.

The benzodiazepine-alcohol of formula VI is preferably obtained via step (c) in an addition reaction of an alkali salt of the benzodiazepine of formula IV to propionaldehyde. The alkali salt can be prepared using strong bases such as alkali amides, alkali alkyls or alkali silazanes. Preferably lithium diisopropylamide (LDA) or butyl-lithium is used and most preferably lithium diisopropylamide is used. Due to this possible use of strong bases the benzodiazepine-alcohol of formula VI can also be present in its deprotonized form, i.e. the corresponding benzodiazepine-alcoholate is present. The solvent for this reaction should be inert to strong bases and is in particular chosen from ethers or aromatic hydrocarbons. Ethers are preferred, with the most preferable solvent being THF. Usual reaction temperatures range from -50 °C to room temperature, preferably from -30 °C to 0 °C.

The benzodiazepine of formula IV can be synthesised by reacting 3H-[1,5]benzodiazepine-2,4-diamine (*J. Chem. Soc., Chem. Commun.* 1973, 367-368) and 1-methylpiperazine. The reaction can be carried out in a mixture of solvents comprising toluene and dimethyl sulfoxide. The reaction temperature may vary from 60°C to 180°C, preferably from 90°C to 150°C and is most preferably about 120°C.

The compounds according to formulae III to VII mentioned hereinbefore or salts thereof as well as their use for the manufacture of Olanzapine are further objects of the invention.

5 By the term "or salts thereof" is meant that the compound can not only be present in the form as is shown by formulae I to VII but can also be present in the form of a salt e.g. a salt formed of an organic or inorganic base and an acidic part of the compound such as the alcohol group or a salt formed of an organic
10 or inorganic acid and a basic part of the compound such as the amino-groups. The conversion of one of the substances claimed into its salt or back into the form as is shown by formulae I to VII is within the scope of the invention. This also applies, when this conversion is performed as part of another reaction.

15

The invention is further illustrated with reference to the following examples.

Examples:

20

Example 1

Preparation of 2,4-bis(4-methyl-1-piperaziny1)-3H-[1,5]benzodiazepine (IV).

25

3H-[1,5]Benzodiazepine-2,4-diamine (32.50 g, 160 mmol, 86 %) was added to a solution of dimethyl sulfoxide (220 ml), toluene (220 ml) and 1-methylpiperazine (165 ml). The mixture was heated for 16 h at 120 °C. After cooling the product precipitated. It was
30 filtered off and washed with isopropyl ether (80 ml) to give 40.1 g (74 %) of the title compound as off-white needles. The second crop was obtained by adding isopropyl ether (410 ml) to the filtrate. The mixture was allowed to stand overnight at 4 °C, the crystallised product was filtered off to give additional
35 4.25 g (8 %) of the title compound. For analytical purposes the product was recrystallised from ethyl acetate.

M.P. 227-228 °C (ethyl acetate).

$^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ = 2.21 (s, 6H), 2.35 (m, 8H), 3.02 (broad s, 2H), 3.54 (m, 8H), 6.88 (m, 2H), 7.01 (m, 2H).

HRMS calcd. for $\text{C}_{19}\text{H}_{28}\text{N}_6$: 340.2375 found: 340.2387.

5

Example 2

Preparation of 1-[2,4-bis(4-methyl-1-piperazinyl)-3H-[1,5]benzo-
10 diazepin-3-yl]-1-propanol (VI).

A suspension of 2,4-bis(4-methyl-1-piperazinyl)-3H-[1,5]benzo-
diazepine (17.024 g, 50 mmol) in tetrahydrofuran (200 ml) under
constant flow of argon was cooled to -30 °C. A solution of lith-
ium diisopropylamide (LDA) (2 M, 37.5 ml, 75 mmol) was added
15 dropwise. Thus obtained dark brown suspension was allowed to
warm to -5 °C, and then again cooled to -30 °C. Propionaldehyde
(5.50 ml, 75 mmol) was added during 5 min. The resulting pale
brown suspension was allowed to warm to 10 °C, while strongly
agitated water (250 ml) was added. The solution was transferred
20 to a separating funnel, chloroform (150 ml) was added and the
phases were separated. The water phase was extracted with
chloroform (2 x 50 ml). The combined organic phases were dried
over anhydrous Na_2SO_4 and the solvent was evaporated at reduced
pressure. The crude product was suspended in hexane (750 ml),
25 filtered off and washed with hexane (75 ml) to give 18.34 g (92
%) of the title compound as an off-white powder. For analytical
purposes the product was recrystallised from ethyl acetate.

M.P. 163-166 °C (ethyl acetate).

30 $^1\text{H-NMR}$ (CDCl_3) δ = 0.69 (t, 3H), 1.25 (m, 2H), 2.24 (s, 3H), 2.30
(s, 3H), 2.44 (m, 8H), 3.04 (td, 1H), 3.33 (broad s, 1H), 3.57
(m, 8H), 4.51 (d, 1H), 6.98 (m, 2H), 7.10 (m, 1H), 7.22 (m, 1H).

HRMS calcd. for $\text{C}_{22}\text{H}_{34}\text{N}_6\text{O}$: 398.2794 found: 398.2806.

35

Example 3

Preparation of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine (III).

5

Method A

A suspension of 2,4-bis(4-methyl-1-piperazinyl)-3H-[1,5]benzodiazepine (1.702 g, 5 mmol) in tetrahydrofuran (20 ml) under constant flow of argon was cooled to -30 °C. A solution of lithium diisopropylamide (LDA) (2 M, 3.75 ml, 7.5 mmol) was added dropwise. Thus obtained dark brown suspension was allowed to warm to -5 °C until dissolved and then again cooled to -30 °C. Propionaldehyd (0.54 ml, 7.5 mmol) was added during 5 min. The resulting clear yellow solution was allowed to warm to -5 °C, triethylamine (5.55 ml, 40 mmol) and pyridine (0.040 ml, 0.5 mmol) were added. A solution of trifluoroacetic anhydride (4.2 ml, 30 mmol) in tetrahydrofuran (6 ml) was added dropwise maintaining the temperature at -5 °C. The reaction mixture was stirred for another hour. Methanol (5 ml) and while strongly agitated NaOH (1 M, 35 ml) were added dropwise. The reaction mixture was stirred for four hours while slowly warming to room temperature. The solution was made acidic at pH of 1 and extracted with dichloromethane (3 x 25 ml). The water phase was made alkalic at a pH of 10 and extracted with diethyl ether (15 x 25 ml). After each extraction water phase was adjusted to pH of 10. The ether phase was dried over anhydrous Na₂SO₄ and ether was evaporated at reduced pressure to give 1, 701 g (89 %) of the title compound as a yellow resin.

30 ¹H-NMR (CDCl₃) δ = 0.76 (t, 3H), 1.97 (m, 2H), 2.34 (s, 6H), 2.45 (m, 8H), 3.69 (m, 8H), 5.32 (t, 1H), 6.95 (m, 2H), 7.16 (m, 2H). HRMS calcd. for C₂₂H₃₂N₆: 380.2688 found: 380.2697.

Method B

35 To a suspension of 1-[2,4-bis(4-methyl-1-piperazinyl)-3H-[1,5]benzodiazepin-3-yl]-1-propanol (1.195 g, 3 mmol), triethylamine (2.50 ml, 18 mmol) and pyridine (0.024 ml, 0.3 mmol) in tetrahydrofuran (10 ml) under constant flow of argon,

at 0 °C, a solution of trifluoroacetic anhydride (1.26 ml, 9 mmol) in tetrahydrofuran (5 ml) was added dropwise. The reaction mixture was stirred for another hour at 0 °C. Methanol (5 ml) was added. The solution was allowed to warm to 10 °C, while 5 strongly agitated NaOH (1 M, 20 ml) was added dropwise. Dichloromethane (30 ml) was added and the phases were separated. The organic phase was dried over anhydrous Na₂SO₄ and the solvent was evaporated at reduced pressure. The crude product was suspended in isopropyl ether (8 ml) and filtered off. The filtrate 10 was evaporated at reduced pressure to give 0.971 g (84 %) of the title compound as a yellow resin. The product obtained was characterized using ¹H-NMR spectroscopy and was found to be identical to the product obtained by method A.

15 Method C

To a suspension of 1-[2,4-bis(4-methyl-1-piperazinyl)-3H-[1,5]benzodiazepin-3-yl]-1-propanol (19.93 g, 50 mmol) and triethylamine (45 ml, 325 mmol) in dichloromethane (100 ml) under constant flow of argon, at 0 °C, a solution of 20 trifluoroacetic anhydride (21 ml, 150 mmol) in dichloromethane (50 ml) was added dropwise. The reaction mixture was stirred for another hour at 0 °C. The solution was allowed to warm to room temperature. Methanol (66 ml) and tetrabutylammonium bromide (1.61 g, 5 mmol) were added successively. While strongly agi- 25 tated NaOH (1 M, 660 ml) was added dropwise. Two phase system was agitated for two hours. The phases were separated and the water phase was extracted with dichloromethane (2 x 100 ml). The organic phase was dried over anhydrous Na₂SO₄ and the solvent was evaporated at reduced pressure. The crude product was suspended 30 in isopropyl ether (150 ml) and filtered off. the filtrate was evaporated at reduced pressure to give 14.44 g (76 %) of the title compound as a brown resin.

The product obtained was characterised using ¹H-NMR sprectrosopy and was found to be identical to the product obtained by method 35 A.

Method D

A suspension of 2,4-bis(4-methyl-1-piperazinyl)-3H-[1,5]benzodiazepine (45.396 g, 133.3 mmol) in tetrahydrofuran (560 ml) under constant flow of argon was cooled to -10°C. A solution of 5 lithium diisopropylamide (LDA) (2M, 100 ml, 200 mmol) was added over a period of 20 min, maintaining the temperature at -10°C. The obtained deep red solution was stirred for 30 min. Propionaldehyde (14.6 ml, 200 mmol) was added dropwise. Triethylamine (148 ml, 1.067 mol) and pyridine (0.54 ml, 6.7 mmol) were added 10 successively. Trifluoroacetic anhydride (93.1 ml, 667 mmol) was added over a period of 50 min, maintaining the temperature at -10°C. The reaction mixture was stirred for 1 h and allowed to warm to -5°C. Methanol (213 ml) and while strongly agitated NaOH (5M, 200 ml, 1.000 mol) were added maintaining the tempera- 15 ture at -5°C. The reaction mixture was allowed to warm to room temperature and stirred over night. The solution was made acidic with 5M HCl to a pH of 3.5. Two phases were formed and the lower layer was extracted with 600 ml and twice with 100 ml of dichloromethane. The aqueous phase was treated with brine (200 ml) 20 and toluene (400 ml) and made alkaline with 5M NaOH to a pH of 10. The phases were separated and the aqueous phase was extracted with toluene (2 X 200 ml). Combined toluene phases were dried over anhydrous Na₂SO₄ and the solvent was evaporated at reduced pressure to give 48.38 g (95%) of the title compound 25 as an amber resin. The product obtained was characterised using ¹H-NMR spectroscopy and was found to be identical to the product obtained by method A.

Example 4

30

Preparation of Olanzapine.

A suspension of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine (11.90 g, 31.3 mmol), sulphur (20.07 g, 35 626 mmol) and triethyl amine (4.34 ml, 31.3 mmol) in dimethyl sulfoxide (100 ml) and 1-propanol (100 ml) was heated at 100 °C for five days. The resulting black suspension was cooled and filtered off and the filtrate was evaporated at reduced pressure

to obtain a viscous black oil. Dichloromethane (600 ml) and HCl (0.2 M, 600 ml) were added and the phases were separated. The organic phase was extracted again with HCl (0.5 M, 100 ml). The combined water phases were made alkaline at a pH of 9 to 10. Dark brown precipitate was filtered off. Dichloromethane (250 ml) was added to the filtrate. The phases were separated and the water phase was extracted with dichloromethane (2 x 60 ml). The organic phase was dried over anhydrous Na_2SO_4 and the solvent was evaporated at reduced pressure. The black oil was combined with precipitate and purified by chromatography on silica gel, eluted with ethyl acetate/triethylamine 50/1 to obtain 1.195 g (12 %) of the title product.

Example 5

15

Preparation of Olanzapine

Method A

To a 0.118 M solution of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine in benzonitrile (50 ml, 5.90 mmol) quinolinium p-toluenesulfonate (3.01 g, 10 mmol) and sulphur (0.64 g, 20 mmol) were added. The reaction mixture was stirred at 140°C for 13.5 h, cooled to 110°C and concentrated (78-80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (35 ml), water (30 ml) was added and the mixture was made acidic with 2M HCl to a pH of 0.9. The phases were separated and the aqueous phase was extracted with dichloromethane (3 X 30 ml). The aqueous phase was made alkaline with 15 % NaOH to a pH of 7.4 and extracted with dichloromethane (2 X 30 ml). The combined dichloromethane phases were dried over anhydrous Na_2SO_4 and the solvent was evaporated at reduced pressure to give 1.91 g of crude Olanzapine. It contained 4.1 mmol (69.5 % yield) of Olanzapine.

35 Method B

To a 0.118 M solution of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine in benzonitrile (50 ml, 5.90 mmol) pyridinium p-toluenesulfonate (2.51 g, 10 mmol) and sul

phur (0.64 g, 20 mmol) were added. The reaction mixture was stirred at 140°C for 13.5 h, cooled to 110°C and concentrated (78-80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (35 ml), water (30 ml) was added and the mixture was made acidic with 2M HCl to a pH of 0.64. The phases were separated and the aqueous phase was extracted with dichloromethane (2 X 30 ml). The dichloromethane phases were reextracted with diluted HCl (2 X 30 ml). The combined aqueous phases were made alkaline with 15 % NaOH to a pH of 7.9 and extracted with dichloromethane (1 X 50 ml, 2 X 30 ml). The organic phase was dried over anhydrous Na₂SO₄. The solvent was evaporated at reduced pressure to give 1.534 g of crude Olanzapine. It contained 3.93 mmol (66.6 % yield) of Olanzapine.

15 Method C

To a 0.118 M solution of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine in benzonitrile (10 ml, 1.18 mmol) 1-methylimidazolium p-toluenesulfonate (0.51 g, 2 mmol) and sulphur (0.128 g, 4 mmol) were added. The reaction mixture was stirred at 140°C for 10 h, then it was cooled to room temperature and left over night. The reaction mixture was heated to 110°C and concentrated (78-80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (10 ml), water (10 ml) was added and the mixture was made acidic with 2M HCl to a pH of 0.9. The phases were separated and the aqueous phase was extracted with dichloromethane (3 X 6 ml). The aqueous phase was made alkaline with 15 % NaOH to a pH of 8.5 and extracted with dichloromethane (6 X 6 ml). The combined dichloromethane phases were dried over anhydrous Na₂SO₄ and the solvent was evaporated at reduced pressure to give 0.313 g of crude Olanzapine. It contained 0.64 mmol (54.2 % yield) of Olanzapine.


Method D

To a 0.118 M solution of 2,4-bis(4-methyl-1-piperazinyl)-3-propylidene-3H-[1,5]benzodiazepine in benzonitrile (10 ml, 1.18 mmol) p-toluenesulfonic acid monohydrate (0.380 g, 2 mmol) and sulphur (0.128 g, 4 mmol) were added. The reaction mixture was stirred at 140°C for 9 h, cooled to 110°C and concentrated (78-


80°C/24-30 mbar) to an oily residue. The residue was dissolved in dichloromethane (15 ml), water (10 ml) was added and the mixture was made acidic with 2M HCl to a pH of 1.0. The phases were separated and the aqueous phase was extracted with dichloromethane (2 X 10 ml). The dichloromethane phases were reextracted with diluted HCl (10 ml). The combined aqueous phases were made alkaline with 15 % NaOH to a pH of 7.9 and extracted with dichloromethane (3 X 30 ml). The organic phase was dried over anhydrous Na_2SO_4 . The solvent was evaporated at reduced pressure to give 0.252 g of crude Olanzapine. It contained 0.61 mmol (51.7 % yield) of Olanzapine.

Claims:

1. Process for the manufacture of Olanzapine of the following formula I or a salt thereof:



by converting a compound of the following formula II or a salt thereof



in which

- (i) R1 and R2 together form $=CH-CH_2-CH_3$, or
- (ii) R1 and R2 are both H, or
- (iii) R1 is H and R2 is $-CH(R3)-CH_2-CH_3$, wherein R3 is a leaving group that can be eliminated together with R1 to result in R1 and R2 together forming $=CH-CH_2-CH_3$,


to give Olanzapine or a salt thereof.

2. Process according to claim 1, in which the leaving group R3 is $-OR4$.
3. Process according to claim 2, in which R4 is H.

4. Process according to claim 2, in which R4 is selected from the group of acyl and sulfonyl and preferably is trifluoroacetyl or methane sulfonyl.


5 5. Process according to any one of claims 1 to 4, in which R1 and R2 together form $=CH-CH_2-CH_3$ and the conversion is performed by reacting the compound of formula II with a source of sulfur.

10 6. Propylidene-benzodiazepine of the following formula III:




or salts thereof.

20 7. Benzodiazepine of the following formula IV:




or salts thereof.

30 8. Benzodiazepin-propanol of the following formula VI:



or salts thereof.

9. Benzodiazepine-ester of the following formula VII:



in which R4 is selected from the group of acyl and sulfonyl and preferably is trifluoroacetyl or methane sulfonyl, or salts thereof.

- 15 10. Use of a compound according to any one of claims 6 to 9 for the manufacture of Olanzapine.
- 20
- 25
- 30
- 35

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP2004/000299

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D495/04 C07D295/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 1 533 235 A (LILLY INDUSTRIES LTD) 22 November 1978 (1978-11-22) cited in the application page 10; claim 1	1-10
A	EP 0 454 436 A (LILLY INDUSTRIES LTD) 30 October 1991 (1991-10-30) cited in the application claims 1,7	1-10
A	CALLIGARO, D.O. ET AL.: "The Synthesis and Biological Activity of some known and Putative Metabolites of the Atypical Antipsychotic Agent Olanzapine (LY170053)" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 1, 1997, pages 25-30, XP002279427 * Schemes 3 and 4 *	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the International search

10 May 2004

Date of mailing of the International search report

02/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Baston, E

INTERNATIONAL SEARCH REPORT

nal Application No

PCT/EP2004/000299

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1533235	A	22-11-1978	AR 221203 A1 15-01-1981
			AT 351547 B 25-07-1979
			AT 898275 A 15-01-1979
			AU 506340 B2 20-12-1979
			AU 8685875 A 26-05-1977
			BE 835932 A1 25-05-1976
			BG 29573 A3 12-12-1980
			CA 1075687 A1 15-04-1980
			CH 613455 A5 28-09-1979
			CH 613454 A5 28-09-1979
			CS 236753 B2 15-05-1985
			DD 123343 A5 12-12-1976
			DE 2552403 A1 12-08-1976
			DK 375479 A ,B, 07-09-1979
			DK 524175 A ,B, 27-05-1976
			ES 443011 A1 01-07-1977
			FR 2292479 A1 25-06-1976
			HK 58681 A 04-12-1981
			HU 172493 B 28-09-1978
			IE 42565 B1 10-09-1980
			IE 42564 B1 10-09-1980
			IL 48502 A 31-01-1980
			IL 54634 A 31-01-1980
			JP 1317931 C 29-05-1986
			JP 51076296 A 01-07-1976
			JP 60044314 B 02-10-1985
			KE 3163 A 16-10-1981
			MY 14982 A 31-12-1982
			NL 7513833 A ,B, 31-05-1976
			NZ 179335 A 13-11-1978
			NZ 185594 A 13-11-1978
			PH 11669 A 19-05-1978
			PH 24534 A 03-08-1990
			PL 100135 B1 30-09-1978
			RO 69912 A1 15-08-1980
			SE 421209 B 07-12-1981
			SE 7513185 A 28-05-1976
			SE 429045 B 08-08-1983
			SE 7812194 A 27-11-1978
			SU 629879 A3 25-10-1978
			SU 626702 A3 30-09-1978
			US 4172831 A 30-10-1979
			US 4115568 A 19-09-1978
			US 4115574 A 19-09-1978
			YU 123482 A1 31-10-1982
			YU 298375 A1 31-10-1982
			ZA 7507344 A 24-11-1976
EP 0454436	A	30-10-1991	AT 127804 T 15-09-1995
			AU 643267 B2 11-11-1993
			AU 7518691 A 07-11-1991
			BG 61710 B2 31-03-1998
			CA 2041113 A1 26-10-1991
			CN 1056693 A ,B 04-12-1991
			CS 9101168 A2 17-12-1991
			CY 1900 A 24-04-1991
			DE 69112895 D1 19-10-1995
			DE 69112895 T2 07-03-1996

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/000299

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0454436	A	DK 454436 T3	13-11-1995
		EP 0454436 A1	30-10-1991
		ES 2078440 T3	16-12-1995
		FI 911986 A	26-10-1991
		FI 971316 A	27-03-1997
		GR 3017877 T3	31-01-1996
		HK 87596 A	24-05-1996
		HU 60503 A2	28-09-1992
		HU 9500335 A3	30-10-1995
		IE 911348 A1	06-11-1991
		IL 97912 A	31-10-1995
		IL 112575 A	17-08-1999
		JP 2527860 B2	28-08-1996
		JP 7089965 A	04-04-1995
		KR 195566 B1	15-06-1999
		LU 90009 A9	31-01-1997
		LU 90869 A9	21-02-2002
		LV 10262 A ,B	20-10-1994
		MX 25502 A ,B	01-10-1993
		NO 911624 A ,B,	28-10-1991
		NZ 237932 A	26-08-1993
		PT 97446 A ,B	31-01-1992
		SI 9110739 A	31-10-1997
		SK 279196 B6	08-07-1998
		RU 2043992 C1	20-09-1995
		US 5229382 A	20-07-1993
		ZA 9103085 A	30-12-1992

CORRECTED VERSION

Rec'd PCT/PTO 07 JUL 2005

10/541604

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065390 A1

(51) International Patent Classification⁷: C07D 495/04,
295/04

(21) International Application Number:
PCT/EP2004/000299

(22) International Filing Date: 16 January 2004 (16.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
103 01 923.5 17 January 2003 (17.01.2003) DE

(71) Applicant (for all designated States except US): KRKA,
TOVARNA ZDRAVIL, D.D., NOVO MESTO [SI/SI];
Smarjeska cesta 6, 8501 Novo mesto (SI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LENARSIC, Ro-
man [SI/SI]; Trzaska cesta 266/B, 1000 Ljubljana (SI).
ZUPET, Rok [SI/SI]; Janeza Rozica 6, 1211 Ljubljana
(SI). BENEDIK, Milena [SI/SI]; Ratez 12, 8321 Brus-
nice (SI). MOHAR, Barbara [—/SI]; National Institute
of Chemistry, Hajdrihova 19, SL-1001 Ljubljana (SI). ŠTI-
MAC, Anton [—/SI]; National Institute of Chemistry, Ha-
jdrihova 19, SL-1001 Ljubljana (SI).

(74) Agents: GROSS, Ulrich-Maria et al.; Uexküll & Stol-
berg, Beselerstrasse 4, 22607 Hamburg (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(48) Date of publication of this corrected version:
16 December 2004


(15) Information about Correction:
see PCT Gazette No. 51/2004 of 16 December 2004, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE



(I)



(II)

(57) Abstract: The invention provides an improved process for preparing Olanzapine as well as intermediates therefor.

WO 2004/065390 A1